|
Book Chapters:
Gautier M, Cohen HJ, Bubis J, Cancer in the Elderly, Chemotherapeutic Treatment Issues in the Elderly, in publication, 2005
Gautier M, Bengtson EM, Liebers EM, Cohen HJ, Geriatric Medicine, 4th Edition, Hematologic Malignancies, Chapter 38, pp 487-508, 2003.
Abstracts:
Bubis JA, Schaal A, Kimtis E, Gautier M, Subcutaneous Administration of Alemtuzumbab: (Abstract) Submitted to Annual Meeting, American Society of Hematology, 2005
Bubis JA, Ely P, Meehan K, Stearns D, Schaal A, Kimtis E, Lowrey C, Bengtson E, Hill J, Gautier M, Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes: (Abstract), Submitted to Annual Meeting, American Society of Hematology, 2005
Gautier M, Bubis J, Wu J, Meehan K, Synergistic Effects of Bortezomib with Low Dose Melphalan Against Human AML Cells: (Abstract), Submitted to Annual Meeting, American Society of Hematology, 2005
Ely P, Stearns D, Zaki B, Fitzmaurice T, Gautier M, Lowrey C, Bengtson E, Hill J, Schaal A, Kimtis E, Root L, Webber S, Szczepiorkowski, Z, Meehan K, Successful PBSC Mobilization, Collection, Transplantation and Engraftment after Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin’s Lymphoma (NHL): (Abstract), Submitted to Annual Meeting, American Society of Hematology, 2005
Bengtson E, Wu J-Y, Fitzmaurice T, Cornell C, Ely P, Gautier M, Hill J, Lowrey C, Meehan K, Immunotherapy Immediately Following Transplantation for Multiple Myeloma: Early Recovery of Aggressive Cytotoxic Cells and Improved Immune Recovery: (Abstract) , Submitted to Annual Meeting, American Society of Hematology, 2004
Rai KR, Byrd JC, Peterson B, Gautier M, Larson RA, Subcutaneous Alemtuzumab Following Fludarbine for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): CALGB Study 19901, Blood, 102:11, 2003
Bengtson E, Fitzmaurice TF, Ely P, Gautier M, Cornell CJ, Lowrey C, Hill JM, Meehan KR. Autologous Peripheral Blood Stem Cell Transplantation and Immunotherapy for Multiple Myeloma Using GM-CSF and Low Dose IL-2: (Abstract) Program Proceedings of the American Society of Clinical Oncology, 22:845a, 2003
|